Pharis Mohideen - 20 Nov 2025 Form 4 Insider Report for DBV Technologies S.A. (DBVT)

Role
Chief Medical Officer
Signature
/s/ Virginie Boucinha, Attorney-in-Fact
Issuer symbol
DBVT
Transactions as of
20 Nov 2025
Transactions value $
$-23,207
Form type
4
Filing time
25 Nov 2025, 16:15:05 UTC
Previous filing
31 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mohideen Pharis Chief Medical Officer C/O DBV TECHNOLOGIES S.A., 107, AVENUE DE LA REPUBLIQUE, CHATILLON, FRANCE /s/ Virginie Boucinha, Attorney-in-Fact 25 Nov 2025 0001760395

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DBVT Ordinary Shares Sale $-18,708 -6,496 -5.92% $2.88 103,153 20 Nov 2025 Direct F1, F2, F3
transaction DBVT Ordinary Shares Sale $-4,498 -1,624 -1.57% $2.77 101,529 21 Nov 2025 Direct F1, F2, F4
transaction DBVT Ordinary Shares Award $0 +44,000 +43.3% $0.000000 145,529 21 Nov 2025 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DBVT Employee Stock Option (right to buy) Award $0 +253,000 $0.000000 253,000 21 Nov 2025 Ordinary Shares 253,000 $2.90 Direct F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares.
F2 Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F3 This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15268 to EURO 1.00 as of November 20, 2025.
F4 This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025.
F5 Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date.
F6 The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date.